GlassScriptPhysician profile
Maria Roxana Timis
NPI 1033747563
$17,711.58
in general payments reported to CMS, 2019-2025
67 companies · $8,927 in 2025
The $8,927 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $943 · 2022: $1,340 · 2023: $3,061 · 2024: $3,440 · 2025: $8,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,146 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,250 · Consulting Fee: $1,260 · Travel and Lodging: $1,206 · Education: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,145.92 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,250.00 |
| Consulting Fee | $1,260.00 |
| Travel and Lodging | $1,206.18 |
| Education | $565.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,903.53 | 2022-2025 | Vectibix, Vectibix, Kyprolis |
| Pfizer INC. | $1,663.03 | 2022-2025 | |
| Janssen Biotech, INC. | $1,075.30 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $887.65 | 2021-2025 | Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $684.84 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $558.97 | 2022-2025 | |
| Incyte Corporation | $486.48 | 2021-2025 | Monjuvi, Jakafi |
| Glaxosmithkline, LLC. | $467.42 | 2021-2025 | Jemperli, Ojjaara, Blenrep |
| Gilead Sciences, INC. | $362.19 | 2022-2025 | Trodelvy |
| Sobi, INC | $330.76 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $303.83 | 2021-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $302.62 | 2023-2025 | |
| Puma Biotechnology, INC. | $296.47 | 2021-2024 | |
| Eisai INC. | $289.51 | 2023-2025 | |
| Daiichi Sankyo INC. | $282.59 | 2021-2025 | Datroway, Enhertu |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $218.65 | 2024 | Myrisk |
| Apellis Pharmaceuticals, INC. | $196.17 | 2022-2025 | Empaveli |
| Celgene Corporation | $185.82 | 2023-2025 | Reblozyl, Pomalyst |
| Genzyme Corporation | $160.89 | 2021-2025 | |
| Abbvie INC. | $158.82 | 2022-2025 | |
| Genmab U.S., INC. | $148.04 | 2024-2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $142.02 | 2023-2024 | |
| Dendreon Pharmaceuticals LLC | $130.80 | 2024-2025 | Provenge |
| Genentech USA, INC. | $129.68 | 2021-2024 | Phesgo |
| Emd Serono, INC. | $124.04 | 2022-2025 | Tepmetko |
| Stemline Therapeutics INC. | $123.87 | 2023-2025 | Orserdu, Elzonris |
| Alexion Pharmaceuticals, INC. | $120.94 | 2022-2024 | Ultomiris |
| Beigene USA, INC. | $115.47 | 2022-2024 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $109.15 | 2022-2025 | Besremi |
| Blueprint Medicines Corporation | $104.95 | 2021-2024 | Ayvakit |
| Lilly USA, LLC | $104.89 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $103.42 | 2023-2025 | Ninlaro, Iclusig, Alunbrig |
| Astellas Pharma US INC | $98.32 | 2025 | Xtandi, Xospata, Vyloy |
| Cti Biopharma Corp. | $91.78 | 2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $84.26 | 2022-2024 | Fotivda |
| Janssen Scientific Affairs, LLC | $83.39 | 2025 | Carvykti, Darzalex, Tecvayli |
| Ipsen Biopharmaceuticals, INC | $80.79 | 2023-2025 | Tazverik, Onivyde, Somatuline Depot |
| Seagen INC. | $75.73 | 2022-2023 | Tukysa |
| Array Biopharma INC | $74.43 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Mirati Therapeutics, INC. | $68.69 | 2023-2024 | Krazati |
| Epizyme, INC. | $65.91 | 2022 | |
| Karyopharm Therapeutics INC. | $62.17 | 2022-2023 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $61.26 | 2022-2023 | Libtayo |
| Rigel Pharmaceuticals, INC. | $50.12 | 2021-2023 | Tavalisse, Rezlidhia |
| Tempus Ai, INC | $47.33 | 2024-2025 | Xt Cdx |
| Geron Corporation | $46.36 | 2025 | Rytelo |
| Exelixis INC. | $40.93 | 2022-2025 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.46 | 2025 | |
| Beone Medicines USA, INC. | $30.28 | 2025 | Tevimbra |
| Taiho Oncology, INC. | $27.47 | 2025 | |
| Invivyd INC | $24.31 | 2025 | Pemgarda |
| Servier Pharmaceuticals LLC | $24.06 | 2024 | |
| G1 Therapeutics, INC. | $24.03 | 2023 | Cosela |
| Legend Biotech USA INC. | $23.12 | 2024 | |
| Recordati_rare_diseases_inc. | $21.42 | 2024 | Sylvant |
| Ge Healthcare | $20.97 | 2022 | |
| Pharmacosmos Therapeutics INC. | $20.85 | 2024 | Cosela |
| Adaptive Biotechnologies Corporation | $20.59 | 2024 | Clonoseq |
| Iovance Biotherapeutics, INC. | $20.01 | 2024 | Amtagvi |
| Kyowa Kirin, INC. | $17.17 | 2023 | Poteligeo |
| Adc Therapeutics America, INC. | $15.88 | 2022 | |
| Blue Earth Diagnostics | $15.24 | 2021 | |
| Springworks Therapeutics, INC. | $14.67 | 2024 | Ogsiveo |
| Caris Mpi, INC. | $14.28 | 2025 | Mi Cancer Seek |
| Agios Pharmaceuticals, INC. | $13.83 | 2023 | Pyrukynd |
| Novocure INC. | $12.18 | 2022 | |
| Pharmaand Gmbh | $10.48 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Timis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.